307 results on '"Jennings, Nicholas B."'
Search Results
2. Enhancing oral delivery of plant-derived vesicles for colitis
Catalog
Books, media, physical & digital resources
3. Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer
4. Endothelial p130cas confers resistance to anti-angiogenesis therapy
5. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer
6. CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance
7. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status
8. Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype
9. Mechanism and rational combinations with GP‐2250, a novel oxathiazine derivative, in ovarian cancer.
10. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models
11. Assessment of cost sharing in the Pima County Marketplace
12. Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
13. Measurement characteristics of a concept classification exam using multiple case examples: A Rasch analysis
14. ATP11B mediates platinum resistance in ovarian cancer
15. Abstract 2720: Enhancing oral delivery of plant-derived vesicles
16. Data from Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth
17. Data from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
18. Supplementary Figures from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
19. Data from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
20. Supplementary Figures 1-6 from Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth
21. Supplementary Figures 1-12 from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
22. Supplementary Tables 1-2 from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
23. Figure S1 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
24. Supplementary data from Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability
25. Data from Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
26. Supplementary Figures 1 - 3 from Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
27. Supplementary Data from EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma
28. Supplementary Video 1 from Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
29. Supplementary Video 2 from Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
30. Supplementary Figure 1 from Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma
31. Supplementary Video 3 from Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
32. Data from Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
33. Supplemental Figures 1-4 from Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer
34. Supplementary Figures 1 - 6 and Tables 1 - 10 from Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib
35. Supplementary Figure 2 from Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma
36. Supplementary Figure 1 from Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma
37. Supplementary information from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
38. Supplementary Data from Therapeutic Targeting of ATP7B in Ovarian Carcinoma
39. Supplementary Methods from Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma
40. Supplementary Figure 3 from Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma
41. Supplementary Figure 2 from Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer
42. Supplementary Table 1 from Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer
43. Data from Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer
44. Supplementary Table 2 from Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer
45. Supplementary Figure 1 from Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer
46. Supplementary Table 3 from Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer
47. Supplementary Methods, Legends for Tables 1-3, Figures 1--2 from Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer
48. Endothelial p130cas confers resistance to anti-angiogenesis therapy
49. Biologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma
50. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.